Linagliptin: A thorough Characterization beyond Its Clinical Efficacy

Linagliptin, one of the five dipeptidyl peptidase-4 inhibitors available, has recently entered the market both in the US and in most European countries for treatment of type 2 diabetes mellitus. It presents a xanthine-based structure, and is characterized by unique pharmacokinetics, with non-linear...

Descripción completa

Detalles Bibliográficos
Autores principales: Sortino, Maria Angela, Sinagra, Tiziana, Canonico, Pier Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581698/
https://www.ncbi.nlm.nih.gov/pubmed/23550180
http://dx.doi.org/10.3389/fendo.2013.00016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581698/
https://www.ncbi.nlm.nih.gov/pubmed/23550180
http://dx.doi.org/10.3389/fendo.2013.00016

Ejemplares similares